Exhibit 99.1 Highlighting our commercial progress, the company announces revenues for the 12 months ending June 30, 2023, of A$8.686million, an increase of +A$1.891m; +28% compared with 2022. Momentum building - Growth and Partnerships: The dedication of our team, and the power of geneType, have ignited a revolution in healthcare. We are seeing encouraging growth in our commercial volumes for geneType, a testament to the value and trust we are building in the medical community. Twenty medical practices in b ...

Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EX- CHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SEC ...

Genetic Technologies Limited (NASDAQ:GENE) Q1 2023 Earnings Conference Call November 3, 2022 8:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Adrian Mulcahy [Starts Abruptly] Genetic Technologies First Quarter FY '23 Investor Webinar. We have with us today, which is great news, is Simon Morriss, the CEO of Genetic Technologies. And the way we're going to run this is, Simon is going to go through some prepared slides, he's going to talk through some ...

Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...

Genetic Technologies Limited (NASDAQ:GENE) Q3 2022 Earnings Conference Call April 20, 2022 6:00 PM ET Company Participants Simon Morriss – Chief Executive Officer Mike Tonroe – Chief Financial Officer Dr. George Muchnik – Non-Executive Director and Medical Advisor Conference Call Participants MichaelTonroe Hello and welcome to our Quarter Three business update. I'm Mike Tonroe, Chief Financial Officer Genetic Technologies. I'm also your house and moderator. Thank you for taking the time to join us today. Th ...

Exhibit 99.41 HALF YEAR REPORT Genetic Technologies Limited Appendix 4D Half-year ended 31 December 2021 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 Half-year ended: 31 December 2021 Previous period: 31 December 2020 Results for announcement to the market | | | | | $ | | --- | --- | --- | --- | --- | | Revenue for ordinary activities | Up | 12,379% | to | 2,051,016 | | Net loss after tax (from ordinary activities) for the period | | | | | | attributable to members | Up | (11.7)% | to | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR (Address of principal executive offices) Simon Morriss, Chief Executive O ...

Genetic Technologies Limited (NASDAQ:GENE) Quarterly Investor Webinar January 27, 2021 7:30 PM ET Company Participants Stephanie Ottens - Investor Relations George Muchnicki - Acting Chief Executive Officer Peter Rubinstein - Chairman Richard Allman - Chief Scientific Officer Conference Call Participants Stephanie Ottens Good morning and welcome everyone to Genetic Technologies Quarterly Investor Webinar. And we have the pleasure this morning to have from Genetic, Dr. George Muchnicki, Acting CEO on the res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR [ ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...